11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Hydrocortison Galen

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Hydrokortison – systemiskt

Hydrokortison – systemiskt

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.

  2. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14:177-86.

  3. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54.

  4. Solu-Cortef (hydrocortisone). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.

  5. Charmandari E, Hindmarsh PC, Johnston A, Brook CG. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab. 2001;86:2701-8.

  6. Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). J Pediatr Endocrinol Metab. 2012;25:977-81.

  7. Hochberg Z, Schechter J, Benderly A, Leiberman E, Rosler A. Growth and pubertal development in patients with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency. Am J Dis Child. 1985;139:771-6.

  8. Belgorosky A, Chahin S, Rivarola MA. Elevation of serum luteinizing hormone levels during hydrocortisone treatment in infant girls with 21-hydroxylase deficiency. Acta Paediatr. 1996;85:1172-5.

  9. Werumeus Buning J, Kootstra-Ros JE, Brummelman P, van den Berg G, van der Klauw M, Wolffenbuttel BH et al. Higher hydrocortisone dose increases bilirubin in hypopituitary patients- results from an RCT. Eur J Clin Invest. 2016;46:475-80.

  10. Yu TJ, Liu YC, Yu CC, Tseng JC, Hua CC, Wu HP. Comparing hydrocortisone and methylprednisolone in patients with septic shock. Adv Ther. 2009;26:728-35.

  11. Karemaker R, Heijnen CJ, Veen S, Baerts W, Samsom J, Visser GH et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res. 2006;60:745-50.

  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-09.]

  1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.
  2. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14:177-86.
  3. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54.
  4. Solu-Cortef (hydrocortisone). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.
  5. Charmandari E, Hindmarsh PC, Johnston A, Brook CG. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab. 2001;86:2701-8.
  6. Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). J Pediatr Endocrinol Metab. 2012;25:977-81.
  7. Hochberg Z, Schechter J, Benderly A, Leiberman E, Rosler A. Growth and pubertal development in patients with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency. Am J Dis Child. 1985;139:771-6.
  8. Belgorosky A, Chahin S, Rivarola MA. Elevation of serum luteinizing hormone levels during hydrocortisone treatment in infant girls with 21-hydroxylase deficiency. Acta Paediatr. 1996;85:1172-5.
  9. Werumeus Buning J, Kootstra-Ros JE, Brummelman P, van den Berg G, van der Klauw M, Wolffenbuttel BH et al. Higher hydrocortisone dose increases bilirubin in hypopituitary patients- results from an RCT. Eur J Clin Invest. 2016;46:475-80.
  10. Yu TJ, Liu YC, Yu CC, Tseng JC, Hua CC, Wu HP. Comparing hydrocortisone and methylprednisolone in patients with septic shock. Adv Ther. 2009;26:728-35.
  11. Karemaker R, Heijnen CJ, Veen S, Baerts W, Samsom J, Visser GH et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res. 2006;60:745-50.
  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-09.]